KC
Therapeutic Areas
IDEAYA Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Darovasertib (IDE196) | Cancers with GNAQ or GNA11 mutations (e.g., uveal melanoma) | Phase 2/3 |
| IDE397 | Solid tumors with MTAP gene deletion | Phase 1 |
| IDE892 | MTAP-deleted solid tumors | Phase 1 |
| IDE161 | Tumors with homologous recombination deficiency (HRD) | Phase 1 |
| IDE849 | Not explicitly stated (DLL3-targeting ADC) | Not Specified |
| IDE705 | Synthetic lethality (Pol Theta inhibitor) | Preclinical |
| IDE275 | Synthetic lethality (Werner Helicase inhibitor) | Preclinical |
Leadership Team at IDEAYA Biosciences
YS
Yujiro S. Hata
President and Chief Executive Officer, Founder
DM
Darrin M. Beaupre, M.D., Ph.D.
Chief Medical Officer
MW
Michael White, Ph.D.
Chief Scientific Officer
T(
Theodora (Theo) Ross, M.D., Ph.D.
Chief Development Officer
JB
Joshua Bleharski, Ph.D.
Chief Financial Officer
SD
Stu Dorman
Chief Commercial Officer
DB
Douglas B. Snyder
Chief Legal Officer
DA
Daniel A. Simon
Chief Business Officer
FZ
Francine Zelaya
Senior Vice President, Head of Human Resources
PA
Paul A. Barsanti, Ph.D.
Chief Technology Officer